Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Baxter
Accenture
US Army
Cipla

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 10,324,088

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,324,088
Title:Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
Abstract: The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn\'s disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-.alpha.4.beta.7 integrin drug.
Inventor(s): Singh; Sharat (San Diego, CA), Jain; Anjali (San Diego, CA), Kondragunta; Venkateswarlu (San Diego, CA)
Assignee: NESTEC S.A. (Vevey, CH)
Application Number:15/601,921
Patent Claims:see list of patent claims

Details for Patent 10,324,088

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up NESTEC S.A. (Vevey, CH) 2034-12-02 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up NESTEC S.A. (Vevey, CH) 2034-12-02 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up NESTEC S.A. (Vevey, CH) 2034-12-02 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up NESTEC S.A. (Vevey, CH) 2034-12-02 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up NESTEC S.A. (Vevey, CH) 2034-12-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
QuintilesIMS
Cantor Fitzgerald
Harvard Business School
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.